Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance

BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)

January 25, 2019 8:45 AM EST

BMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following the company's 4Q earnings report. Arfaei remains comfortable with Bristol's independent business: from 2018 to 2022, BMO Capital forecasts revenue and EPS CAGRs of 5% and 8%,... More